Focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs.

Mighty Therapeutics, together with its wholly owned operating subsidiary, Stealth BioTherapeutics Inc., is advancing novel therapies for people living with diseases involving mitochondrial dysfunction.

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity.

Clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer and other immune-mediated conditions.

Clinical-stage drug development company focused on developing novel targeted therapies for Alzheimer's disease.

Clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders.

A clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia.

Clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

Clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.

Clinical-stage drug development company pioneering precision psychiatry by developing targeted medicines to help patients get better faster.

Clinical-stage precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates.

Clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders.

Clinical-stage immunology focused biopharmaceutical company developing therapies for atopic dermatitis and asthma.

Clinical-stage drug development company pioneering transformative medicines to treat inflammatory and fibrotic diseases by targeting the endocannabinoid system.

Clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers.

Clinical-stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects

Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization.

Clinical-stage biopharmaceutical company leveraging a proprietary microRNA-based target discovery platform to develop first-in-class small molecule and antibody cancer therapeutics.

Clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases.

Clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics called engineered toxin bodies (ETBs).

Clinical-stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies for cancer.

Clinical stage biotechnology company developing therapeutics targeting stress support pathways.

Clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment.

Dedicated to creating life-changing T Cell therapies for patients by unleashing the untapped potential of the human immune system.

Commercial-stage biopharmaceutical company developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology.